bioMérieux (BIM) H1 2025 earnings summary

Executive summary

• Achieved 9.4% organic sales growth in H1 2025, reaching €2,044 million, driven by strong performance in molecular diagnostics, industrial applications, and BIOFIRE® respiratory panels.

• Profitability improved with CEBIT/EBIT margin rising to 18.2% of sales, reflecting efficiency gains and the GO-28 strategic plan.

• Free cash flow more than tripled to €170 million, supported by EBITDA growth and working capital improvements.

• Net income declined 25% to €161 million due to a €146 million impairment on Reveal technology; excluding this, net income was up 45% year-over-year.

• Multiple new product launches and strategic acquisitions, including SpinChip Diagnostics, Day Zero Diagnostics, and Neoprospecta, strengthened the portfolio.

Financial highlights

• H1 2025 net sales reached €2,044 million, up 9.4% at constant exchange rates, with a €34 million negative currency effect.

• Gross profit margin increased to 57.1% (+80bps year-over-year), driven by favorable product mix and pricing.

• CEBIT/EBIT margin improved to 18.2% (+210bps year-over-year), with CEBIT at €372 million.

• Net debt at €126 million, representing 0.1x twelve-month EBITDA.

• CapEx stable at 7.5% of sales, focused on US and French manufacturing and installed base expansion.

Outlook and guidance

• 2025 organic sales growth guidance revised to 6–7.5% due to China market decline.

• CEBIT/EBIT growth guidance raised to 12–18% for 2025, reflecting strong H1 performance and efficiency gains.

• Tariff impacts estimated at €5–10 million in 2025 and €35 million in 2026, with mitigation actions underway.

• FX impact on FY25 CEBIT estimated at –€25 million.

• CapEx guidance lowered to 9% of sales for the year.